Evidence map›Paper›PMID 42733592›Full record

ReviewCell insight2026

Construction and application of mammary and breast cancer organoids.

Yuan Meng, Pinyang Bai, Lingxian Zhang, Mengna Zhang, Cheguo Cai

Abstract readReview
In one paragraph

Review in Cell insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuan MengKey Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, Zhejiang, 310024, China.
Pinyang BaiKey Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, Zhejiang, 310024, China.
Lingxian ZhangKey Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, Zhejiang, 310024, China.
Mengna ZhangKey Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, Zhejiang, 310024, China.
Cheguo CaiKey Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, Zhejiang, 310024, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mammary organoids and breast cancer organoids (BCOs) have become indispensable models for investigating mammary development, tumorigenesis, therapeutic response, and drug resistance. In this review, we summarize current strategies for constructing mammary organoids from adult mammary stem cells, pluripotent stem cells and immortalized mammary epithelial cell lines, and discuss how these models recapitulate key physiological processes. Additionally, we elaborate on four complementary approaches for building BCOs, including patient-derived tumor organoids (PDOs), gene-edited models, microenvironment reconstruction via multicellular co-culture, and organoid-on-a-chip platforms. Notably, we outline major applications of mammary organoids in developmental biology and translational fields, and emphasize the expanding roles of BCOs in living biobanks, mechanistic studies, high-throughput drug screening, personalized drug sensitivity testing, and immunotherapy response prediction. Finally, we point out key challenges including standardization, long-term genetic and phenotypic stability, vascularization, immune-context integration, and optimization of dynamic culture conditions, and propose directions to improve model fidelity and clinical utility.

Indexed as

ApplicationBreast cancerMammary glandOrganoid

Identifiers

PMID42733592
PMCPMC13571315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.